All lobbying filings

THE MCMANUS GROUP

Lobbying for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Represents the leading research-based pharmaceutical companies in the US.

Filing 3rd Quarter - Report

3rd Quarter (July 1 - Sep 30) 2025 · District of Columbia · House · Senate · $60,000.00 income · posted Oct 20, 2025

Official filing document

Bills named in this filing 3

S 839
Safeguarding Honest Speech Act
HR 1492
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic can…
HR 4299
Protecting Patient Access to Cancer and Complex Therapies Act

Lobbying activity 2

Medicare/Medicaid

Access and reimbursement in Medicare Parts B and D. Implementation of provisions included in Subtitle B of PL.117-169- Inflation Reduction Act of 2022. Support for EPIC Act - S. 839, and H.R. 1492, To equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act Policies related to the Most Favored Nation Drug Pricing Model

Health Issues

Issues related to reforming and increasing transparency within the 340B Drug Pricing Program.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.